CRBP
Corbus Pharmaceuticals Holding
7.90$
+2.9%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +95.1% | +38.9% | +274.4% | -29.8% | +4.6% | +108.2% | +5.3% | -38.4% | -57.4% | +451.4% | +7.9% | |
| – | +94.6% | +36.9% | +276.4% | -32.5% | -13.8% | +141.3% | +8.8% | -39.9% | -60.9% | +549.7% | +9.1% | |
| – | +97.0% | +21.5% | +317.1% | -33.2% | -24.0% | +169.1% | -70.7% | -32.0% | -19.3% | +25.3% | +65.7% | |
| – | +97.0% | +21.5% | +317.1% | -33.2% | -24.0% | +169.1% | +14.3% | -39.4% | -64.7% | +613.0% | +10.0% | |
| – | – | – | – | – | – | -3.8% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +129.7% | +250.6% | +229.2% | +88.8% | +87.9% | +83.3% | -24.8% | -21.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +427.1% | +130.5% | +2.5% | +111.7% | +120.8% | +32.7% | -32.3% | -13.7% | +5.6% | -61.8% | +53.8% | |
| – | +391.8% | +145.1% | -7.8% | +120.5% | +92.9% | -8.6% | -46.7% | -25.7% | +152.3% | -62.9% | +75.1% | |
| – | -377.2% | – | +22.5% | +18.6% | +241.6% | +27.1% | +191.6% | -11.4% | +298.3% | -90.9% | +1.7% | |
| – | +281.9% | +160.2% | -8.5% | +102.7% | +74.8% | -33.5% | -75.9% | +22.0% | +46.2% | +50.6% | -53.7% | |
| – | – | – | -100.0% | – | – | – | -13.3% | +2.2% | – | – | – | |
| – | +53.3% | -0.7% | +547.9% | -52.4% | -77.6% | +635.3% | +52.6% | -52.3% | -120.9% | – | +3.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +55.5% | +31.2% | +22.0% | +13.6% | +12.1% | +22.3% | +57.4% | +1.7% | +3.8% | +152.2% | +22.0% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.